Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record.

A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

Open access
Jin, Zhe, Cheng, Yulan, Gu, Wen, Zheng, Yingye, Sato, Fumiaki, Mori, Yuriko, Olaru, Alexandru V., Paun, Bogdan C., Yang, Jian, Kan, Takatsugu, Ito, Tetsuo, Hamilton, James P., Selaru, Florin M., Agarwal, Rachana, David, Stefan, Abraham, John M., Wolfsen, Herbert C., Wallace, Michael B., Shaheen, Nicholas J., Washington, Kay, Wang, Jean, Canto, Marcia Irene, Bhattacharyya, Achyut, Nelson, Mark A., Wagner, Paul D., Romero, Yvonne, Wang, Kenneth K., Feng, Ziding, Sampliner, Richard E., Meltzer, Stephen J.·2009·Cancer Research

Abstract

Esophageal adenocarcinoma risk in Barrett's esophagus (BE) is increased 30- to 125-fold versus the general population. Among all BE patients, however, neoplastic progression occurs only once per 200 patient-years. Molecular biomarkers are therefore needed to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression. We therefore performed a retrospective, multicenter, double-blinded validation study of eight BE progression prediction methylation biomarkers. Progression or nonprogression were determined at 2 years (tier 1) and 4 years (tier 2). Methylation was assayed in 145 nonprogressors and 50 progressors using real-time quantitative methylation-specific PCR. Progressors were significantly older than nonprogressors (70.6 versus 62.5 years; P < 0.001). We evaluated a linear combination of the eight markers, using coefficients from a multivariate logistic regression analysis. Areas under the ROC curve (AUC) were high in the 2-year, 4-year, and combined data models (0.843, 0.829, and 0.840; P < 0.001, <0.001, and <0.001, respectively). In addition, even after rigorous overfitting correction, the incremental AUCs contributed by panels based on the 8 markers plus age versus age alone were substantial (Δ-AUC = 0.152, 0.114, and 0.118, respectively) in all 3 models. A methylation biomarker–based panel to predict neoplastic progression in BE has potential clinical value in improving both the efficiency of surveillance endoscopy and the early detection of neoplasia. [Cancer Res 2009;69(10):4112–5]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-0028

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 222

Metadata

Authors
Jin, Z., Cheng, Y., Gu, W., Zheng, Y., Sato, F., Mori, Y., Olaru, A. V., Paun, B. C., Yang, J., Kan, T., Ito, T., Hamilton, J. P., Selaru, F. M., Agarwal, R., David, S., Abraham, J. M., Wolfsen, H. C., Wallace, M. B., Shaheen, N. J., Washington, K., Wang, J., Canto, M. I., Bhattacharyya, A., Nelson, M. A., Wagner, P. D., Romero, Y., Wang, K. K., Feng, Z., Sampliner, R. E., & Meltzer, S. J.
Venue
Cancer Research
Published
2009-05-15
Volume
69
Issue
10
Pages
4112-4115
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2056327333
Cited by
222
References
0
FWCI
16.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-0028
The paper
Jin, Z., Cheng, Y., Gu, W., Zheng, Y., Sato, F., Mori, Y., Olaru, A. V., Paun, B. C., Yang, J., Kan, T., Ito, T., Hamilton, J. P., Selaru, F. M., Agarwal, R., David, S., Abraham, J. M., Wolfsen, H. C., Wallace, M. B., Shaheen, N. J., . . . Meltzer, S. J. (2009). A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-0028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.